Assertio Therapeutics (NASDAQ: ASRT) reported Q4 EPS of ($0.03), $0.01 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $32.18 million versus the consensus estimate of $28.67 million.

GUIDANCE:

Assertio Therapeutics sees FY2025 revenue of $108-123 million, versus the consensus of $123.7 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.